% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zappa:284761,
      author       = {E. Zappa and A. Vitali and K. Anders$^*$ and J. J. Molenaar
                      and J. Wienke and A. Künkele$^*$},
      title        = {{A}doptive cell therapy in paediatric extracranial solid
                      tumours: current approaches and future challenges.},
      journal      = {European journal of cancer},
      volume       = {194},
      issn         = {0014-2964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-02072},
      pages        = {113347},
      year         = {2023},
      abstract     = {Immunotherapy has ignited hope to cure paediatric solid
                      tumours that resist traditional therapies. Among the most
                      promising methods is adoptive cell therapy (ACT).
                      Particularly, ACT using T cells equipped with chimeric
                      antigen receptors (CARs) has moved into the spotlight in
                      clinical studies. However, the efficacy of ACT is challenged
                      by ACT-intrinsic factors, like lack of activation or T cell
                      exhaustion, as well as immune evasion strategies of
                      paediatric solid tumours, such as their highly
                      immunosuppressive microenvironment. Novel strategies,
                      including ACT using innate-like lymphocytes, innovative cell
                      engineering techniques, and ACT combination therapies, are
                      being developed and will be crucial to overcome these
                      challenges. Here, we discuss the main classes of ACT for the
                      treatment of paediatric extracranial solid tumours, reflect
                      on the available preclinical and clinical evidence
                      supporting promising strategies, and address the challenges
                      that ACT is still facing. Ultimately, we highlight
                      state-of-the-art developments and opportunities for new
                      therapeutic options, which hold great potential for
                      improving outcomes in this challenging patient population.},
      subtyp        = {Review Article},
      keywords     = {Adoptive cell therapy (Other) / CAR-T cells (Other) / NK
                      cells (Other) / NKT cells (Other) / Paediatric tumour
                      (Other) / TCR-T cells (Other) / γδ T cells (Other)},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37832507},
      doi          = {10.1016/j.ejca.2023.113347},
      url          = {https://inrepo02.dkfz.de/record/284761},
}